University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
School of Medicine Publications and
Presentations

School of Medicine

2-2021

Hyperglycemia and dyslipidemia: Reduced HLA-DR expression in
monocyte subpopulations from diabetes patients
Blanca I. Restrepo
Marcel Twahirwa
Chinnaswamy Jagannath

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub
Part of the Medicine and Health Sciences Commons

HHS Public Access
Author manuscript
Author Manuscript

Hum Immunol. Author manuscript; available in PMC 2022 August 16.
Published in final edited form as:
Hum Immunol. 2021 February ; 82(2): 124–129. doi:10.1016/j.humimm.2020.11.005.

Hyperglycemia and dyslipidemia: Reduced HLA-DR expression
in monocyte subpopulations from diabetes patients
Blanca I. Restrepoa,b,*, Marcel Twahirwac, Chinnaswamy Jagannathd
aUniversity

of Texas Health Houston, School of Public Health, Brownsville, TX, USA

bUniversity

Author Manuscript

of Texas Rio Grande Valley, School of Medicine, South Texas Diabetes and Obesity
Institute, Edinburg, TX, USA

cDiabetes
dDept.

and Endocrinology Institute, Doctors Hospital at Renaissance, Edinburg, TX, USA

of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX,

USA

Abstract

Author Manuscript

Immune dysfunction contributes to the higher risk of communicable and non-communicable
diseases among diabetics. HLA-DR expression is a robust marker of immune competence in
mononuclear cells, including antigen presentation to CD4 lymphocytes. Given the high prevalence
of obesity among diabetics, we evaluated the independent association between hyperglycemia
and dyslipidemias with respect to HLA-DR expression in blood monocytes from type 2
diabetes patients. The monocytes from individuals with (n=16) or without diabetes (n=25) were
phenotyped by flow cytometry to assess the differential expression of HLA-DR on their three
subpopulations (classical, intermediate and non-classical monocytes). Diabetes was independently
associated with lower HLA-DR expression across all monocyte subpopulations (p <0.05).
Blood triglycerides were associated with further HLA-DR depression (interaction p <0.002).
Cholesterols counterbalanced the reductive effect, with CD36, a receptor for oxidized cholesterol,
correlating with HLA-DR (rho=0.373; p= 0.016). Future studies are warranted to elucidate
the complex interactions between hyperglycemia and dyslipidemias on antigen presentation in
diabetic monocytes.
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Introduction
Patients with diabetes have a higher risk of morbidity, hospitalizations and mortality
from infections, including pulmonary diseases like tuberculosis, streptococcal pneumonia,
influenza and Coronavirus disease-19 (COVID-19) [1]. They are also at higher risk of
certain types of cancers, and of cardiovascular diseases [2]. The high prevalence of these
co-morbidities has been attributed to a dysfunctional immune system in diabetes. Given
the high prevalence of obesity-associated diabetes (up to 90% of adult diabetes patients in
the United States), it is important to understand the contribution of hyperglycemia versus
obesity on the underlying mechanisms driving immune dysfunction in diabetes [3].
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Chronic hyperglycemia is associated with alterations in the phenotype and function of
immune cells, including mononuclear cells which are the focus of this report [4–14]. These
cells play a key role in bridging innate and adaptive immune responses. For example,
in pulmonary infections like tuberculosis, blood monocytes migrate to the lungs, and
differentiate into interstitial macrophages that play a key role in granuloma formation and
bacterial containment. These monocyte-derived macrophages orchestrate the local response,
including the phagocytosis, processing and antigen presentation of bacterial antigenic
peptides via the major histocompatibility complex (MHC) class II (HLA-DR), to CD4 T
cells a major mediator of infection immunity [15].
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Given the critical role of antigen presentation in the ability of monocytes or monocytederived macrophages to connect innate and adaptive responses, we evaluated host factors
associated with expression of MHC-II among blood monocytes from healthy individuals
with or without diabetes. Previous studies have reported lower MHC-II expression in
monocytes from patients with diabetes or transient hyperglycemia, but there are knowledge
gaps. Namely, i) some studies are in critically-ill patients (e.g. sepsis, post-surgery) [16,
17]; ii) it is unclear if altered MHC-II expression is attributed to hyperglycemia or to the
high prevalence of dyslipidemias [9]; and, iii) monocytes are heterogeneous and comprise
three major sub-populations based on their expression of CD14 and CD16, but an altered
MHC-II expression in these sub-groups has not been evaluated in diabetic patients [18].
This is relevant given that evaluation of all monocytes will mainly reflect changes in
the predominant “classical” monocyte compartment, but may be overlooking defects in
the intermediate and non-classical sub-populations which are amplified in inflammatory
conditions and are more specialized in antigen presentation [18].

2.

Materials and Methods
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Healthy Hispanics were enrolled in South Texas and evaluated for diabetes or dyslipidemias
as described [4, 19, 20]. Mononuclear cells were isolated from heparinized blood, stored
frozen (10% DMSO, 20% fetal bovine serum, 70% RPMI) and quick-thawed for batch
phenotyping of baseline monocytes by flow cytometry. The antibodies and gating strategy
to identify the three monocyte subpopulations (CD14+16- or classical, CD14+CD16+
or intermediate and CD14lo,CD16+ or non-classical) was described previously [14]. In
addition, we used anti-HLA-DR-PE-Cy7 (eBioscience clone LN3) and anti-CD36-APC
(Biolegend, clone 5–271). The MFI values were log-transformed for normalization and
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parametric analysis. Data analysis was conducted using SAS 9.4 with p values considered
significant (≤ 0.5) or borderline significant (0.051 – 0.099).

3.

Results
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We enrolled 16 participants with (n=16) or without type 2 diabetes (n=25; Table). Among
the diabetes patients, the mean number of years with the disease was 6.7 (range 0–21 y).
Besides higher glucose and HbA1c, the participants with diabetes were more obese and
had lower HDL cholesterol levels (Table). The phenotyping of their baseline monocytes by
flow cytometry showed no differences in the proportion of monocyte subsets by diabetes
status: classical 80% vs 82%, intermediate 6.1% vs 5.2% or non-classical 12.8% vs 12%
in participants with diabetes vs non-diabetes, respectively (p > 0.05). We next evaluated if
monocytes exhibited differences in the expression of HLA-DR, a broad marker of immune
competence. Among all participants, the intermediate monocyte sub-population had the
highest MFI for HLA-DR, which is consistent with the major role of this subset in antigen
presentation (Table and Fig 1A) [18]. Diabetes or its defining variables [hyperglycemia or
high HbA1c (≥ 6.5%)] were associated with low HLA-DR expression across all monocyte
sub-populations (Fig 1A), but glycemic index among the diabetes patients was not (Table).
Additional host characteristics associated with HLA-DR expression included body-mass
index, the different types of cholesterols and triglycerides. Namely, body-mass index (BMI)
was also inversely correlated with HLA-DR expression, but only for the classical monocyte
subset (Table). Total cholesterol, HDL or low-density cholesterol (LDL) were associated
with higher HLA-DR expression: Total or HDL cholesterol among the classical monocytes,
while LDL cholesterol among the intermediate or non-classical monocytes (Table). Given
the associations between cholesterols and HLA-DR expression, we evaluated if HLA-DR
was correlated with CD36, a scavenger receptor for uptake of LDL cholesterol. Accordingly,
we found a significant correlation between HLA-DR expression and CD36 (linear regression
in Fig 1B). In contrast to cholesterols, participants with high triglycerides had monocytes
with lower HLA-DR expression but differences were not significant (Table).
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To further understand the relationship between monocyte HLA-DR expression and the
host’s diabetic, obese or dyslipidemic status, we took several analytical approaches. First,
we controlled for potential confounders using a one-way ANCOVA with Tukey’s post hoc
test. Even though diabetes patients were more likely to be obese, we found that diabetes
remained independently associated with a lower HLA-DR density after controlling for BMI
(p < 0.05 for all monocyte subsets; Fig 2). We also considered if lipids could be confounders
given that dyslipidemias are frequent co-morbidities in diabetes [20]. However, our study
population had a high proportion of obese individuals even in the non-diabetic participants
(68% in no diabetes and 93.8% in diabetes). Thus, the only lipid with a significant difference
by diabetes status was HDL (Table), but diabetes remained independently associated with
lower HLA-DR expression after controlling for HDL levels (Fig 2).
Second, we evaluated interactions between HLA-DR expression and each lipid type. We
found that the only significant interaction term was HbA1c * triglycerides for all monocytes
(p = 0.002) or the classical subset (p= <0.001; Table), even though triglycerides alone
were not associated with HLA-DR by bi-variable analysis. Third, we stratified the study
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groups by diabetes and either high or low LDL cholesterol or triglycerides levels (Fig 1C).
Consistent with our findings, boxplots showed that diabetics had monocytes with lower
HLA-DR expression, and this reduction was further magnified with high triglycerides,
although differences were only significant among the non-diabetic group. In contrast,
individuals without diabetes and high LDL cholesterol had the highest HLA-DR MFI
for the three monocytes subsets, with this difference being statistically significant for the
intermediate and non-classical monocytes (Fig 1C).

4.

Discussion
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Our findings show lower HLA-DR expression in all the monocyte subsets from diabetes
patients, regardless of their dyslipidemic state. Lipids may further affect HLA-DR
expression, with triglycerides promoting depression, while cholesterols, particularly LDL,
counterbalancing the reductive effect. Our findings complement previous reports of defects
in monocytes and macrophages from diabetes patients or mice, with alterations in phenotype
(e.g. lower MHC-II, adhesins, Fc-receptors) and function (e.g. reduced phagocytosis,
chemotaxis, cytokine expression, response to TLR receptors, higher apoptosis) [4–13]. Our
current findings highlight the further contribution of dyslipidemias towards the altered
phenotype of monocytes from diabetic patients.

Author Manuscript
Author Manuscript

Our results are consistent with some studies in patients with diabetes, but contrast with
the findings from Romano et al, who concluded that HLA-DR reduction was due to
the higher levels of both cholesterol and triglycerides, and not to diabetes [8, 9]. Our
findings in patients are supported by previous in-vitro studies. Exposure of mouse or human
macrophages to a free fatty acid like palmitate (a triglyceride precursor), promoted an
M2 polarization program that included a reduction in HLA-DR expression [21]. Palmitate
mediated this effect by promoting the activation of peroxisome-activated receptor-γ and
increasing endoplasmic reticulum stress. Incubation of macrophages with palmitate plus
high glucose caused a further reduction in HLA-DR expression [21]. In contrast to
triglycerides, in-vitro supplementation with cholesterol leads to an upregulation of HLA-DR
expression and antigen presentation in blood monocytes from healthy individuals [22].
These researchers postulated that a high cholesterol uptake may alter the cholesterol to
phospholipid ratio in the cell membrane, stabilizing HLA-DR expression [22]. Accordingly,
in the classical and non-classical monocytes there was a significant correlation between
HLA-DR expression and CD36, a receptor that facilitates the uptake of oxidized low-density
cholesterol (Fig 1B). Together, the in-vitro and in-vivo studies illustrate the complex
interplay between high glucose, triglycerides and cholesterols on the monocyte phenotype
and their ability to present antigen to T cells. Epidemiological studies are now pointing
towards the joint contribution of diabetes and body-mass index in tuberculosis risk or
outcomes [23–25]. Given that lipids are correlated with body-mass index and are frequently
altered in diabetes, a more detailed understanding of the role of triglycerides and the
different forms of cholesterol in the context of hyperglycemia warrants further studies.
HLA-DR expression has been proposed as a general marker of monocyte immune
competence, with a role in not only in antigen-presentation, but also in the enhancement
of TLR-2 mediated signaling, cellular proliferation, maturation, cytokine production and
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apoptosis [26, 27]. This broader view of HLA-DR is consistent with its identification
in the clinical setting as a biomarker (together with CD64) that distinguished survivors
from non-survivors among diabetic patients with sepsis.[17]. In oncology studies, the
CD14+HLA-DRlo/neg monocytes have not only been shown to have a diminished capacity
to present antigens to T cells, but also to be immunosuppressive and predictive of diminished
responses to anti-tumor responses and/or poor clinical outcomes [28]. Interestingly, type 2
diabetes patients have a higher risk of certain cancers [29]. Thus, the functional and clinical
implications of the lower HLA-DR expression in diabetic monocytes needs further studies.
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In summary, our findings suggest that in diabetes patients, a balance between glucose
control and blood lipids influence HLA-DR expression in baseline monocytes. In
cardiovascular diseases like atherosclerosis, there is an upregulation of HLA-DR antigens,
even in non-immune cells, that reflects a widespread immune activation linked to the
pathology [30]. In contrast, in infections like tuberculosis, higher antigen presentation
is beneficial for infection control, and in fact, M. tuberculosis down-regulates HLA-DR
expression as a part of its evasion from the host’s immune response [31]. From an
evolutionary perspective, one may hypothesize a selective pressure for higher antigen
presentation in young humans to ensure survival from infections. However, in contemporary
times, antibiotics are available and populations are reaching an older age and are more
obese, leading to an increasing prevalence of cardiovascular disease and associated deaths.
Hence, our findings with respect to HLA expression in monocytes are in line with the
broader hypothesis that the tuberculosis epidemic in previous centuries generated a selective
pressure that has led to the high prevalence of metabolic syndrome in contemporary times
[32].
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MHC

Major histocompatibility complex

MFI

Median fluorescence intensity

HDL

high-density cholesterol

LDL

low-density cholesterol

BMI

Body-mass index

TLR

toll-like receptor
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Figure 1. HLA-DR expression in monocyte subsets by diabetes, CD36 or dyslipidemic status.
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PBMCs from healthy controls or diabetes patients were phenotyped by flow cytometry.
After exclusion of dead cells (7AAD-positive), lymphocytes (CD3+ or CD19+) or NK
cells (CD56), monocytes were identified and classified into classical, intermediate or
non-classical sub-populations based on the expression of CD14 or CD16, as described
previously [14]. The median fluorescence intensity (MFI) of HLA-DRII was then analyzed.
A. HLA-DR MFI by HbA1c levels. Differences by normal versus high HbA1c (≥ 6.5%;
vertical dotted line) established by t-test. B. Scatter plots with regression analysis (solid
line) and 95% confidence intervals (dotted lines) of the MFI of HLA-DR versus CD36.
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Each dot represents a participant. C. Boxplots of HLA-DR by diabetes and either LDL
cholesterol or triglyceride levels. HLA-DR MFIs were log-transformed and median rank
scores were compared with post-hoc Dwass, Steel, Critchlow-Fligner to adjust for multiple
comparisons. Differences between study groupsare indicated if p values less than 0.05 (*)
or between 0.051–0.099 (#). The horizontal lines in the box display the median with 25%
and 75% quartiles, and the whiskers show the minimum and maximum values. The open
dot represents the mean. LDL, Low-density cholesterol, with high cutoff values at ≥130
mg/dL; Trig, triglycerides with high cutoff values at ≥150 mg/dL; N, normal values; Hi,
high values; DM, diabetes mellitus.
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Figure 2. Diabetes remains independently associated with HLA-DR expression after controlling
for body-mass index or HDL.

Analysis of covariance (ANCOVA) with Tukey’s post hoc tests indicate that diabetes
remains independently associated with lower HLA-DR expression after controlling for
body mass index or HDL cholesterol, two characteristics that differed by diabetes status
(Table). MFI, median fluorescence intensity; HDL, high-density cholesterol; Significant and
borderline significant p values are highlighted with bold text.
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Study population, and relationship between HLA-DR median fluorescent intensity (MFI) and host factors, by monocyte subpopulation

Author Manuscript
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0.002

2.19 (0.78,
3.59)

Hb1Ac * Triglycerides

Glycemic index = HbA1c * self-reported years with diabetes, among diabetes patients

Fisher’s exact when cells ≤ 5, or chi-square;

a,b

2.17 (0.91,
3.43)

Estimate
(95% CI)

7.56 (0.39)

7.77 (0.43)

p value

7.75 (0.36)

0.175

7.61 (0.37)

Mean
(SD)/Rho

Estimate
(95% CI)

4 (25.0)

12 (75.0)

7.92 (0.4)

p

Interaction model

9 (36.0)
16 (64.0)

0.024

7.79 (0.33)

Mean
(SD)/Rho

<0.001

p value

0.082

p

Classical
(CD14+,CD16lo)

7.78 (0.38)

20 (48.8)

≥ 40 mg/dL

6 (37.5)

p

All monocytes

7.91 (0.36)

21 (51.2)

< 40 mg/dL

10 (41.7)

16 (40.0)

10 (62.5)

n (%)

Diabetes

HLA MFI summarized as Mean (SD) for discrete variables or pearsons rho correlation coefficient for continuous;

b

c

≥ 130 mg/dL

High density cholesterol

14 (58.3)

n (%)

n (%)
24 (60.0)

No diabetes

Participant characteristics summarized as n(%) for discrete variables or mean (SD) for continuous;

a

Author Manuscript

< 130 mg/dL

Author Manuscript
All

Author Manuscript
2.98 (−2.47,
8.42)

Estimate
(95% CI)

9.03 (0.38)

9.08 (0.39)

9.26 (0.35)

8.95 (0.36)

Mean
(SD)/Rho
p

0.283

p value

0.640

Intermediate
(CD14+,CD16+)

2.02 (−1.18,
5.22)

Estimate (95%
CI)

8.46 (0.40)

8.49 (0.35)

8.62 (0.32)

8.4 (0.37)

Mean
(SD)/Rho

0.216

p value

0.844

p

Non-classical
(CD14lo,CD16+)

HLA-DR median fluorescence intensity, by participant characteristicsb

Author Manuscript

Participant characteristicsa
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